Leonard G. Gomella, MD, chairman of the Department of Urology at the Sidney Kimmel Cancer Center, discusses questions that still need to be resolved with biomarkers for the diagnosis and management of patients with prostate cancer.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.